Orange Fruit Roadshow at Central South University Concludes Successfully with Over 10 Cutting-Edge Biomedical Projects Showcased

November 18, 2022, hosted by the Scientific Research Department of Central South University, the Medical-Engineering Integration Professional Committee of the Chinese Society for Biotechnology, and the Sci-Tech Innovation China Working Committee of the Chinese Society for Biotechnology; organized by VCBeat, the Intellectual Property Center of Central South University, Central South University Science Park (Hunan) Development Co., Ltd., the Intellectual Property Research Institute of Central South University, Beijing Yuli Shengke Intellectual Property Agency Co., Ltd., and Shanghai Chuangrui Investment Management Co., Ltd.“Know Central South, Create the Future” Biomedical Roadshow and “Sci-Tech China” High-Value Biomedical Patent Project Selection & Chengguo Roadshow Special Session at Central South University Successfully Concluded in Changsha, Hunan。

To provide more scientists with opportunities for “mutual engagement” with investment firms and industrial enterprises, the event has enlisted the support of numerous industry partners, including Legend Capital, Bohe Angel, Zhongke Innovation, Chuangrui Investment, Danshi Capital, Osmunda, and Ascletis. Minister of the Scientific Research Department, Central South UniversityLi Qihoualso delivered a welcome address for this event.

Photo of Minister Li Qihou’s Address

This Roadshow Session Focuses On"Biopharmaceuticals"field, showcasing the cutting-edge achievements of Central South University’s research team in overcoming challenges in medical fields such as diabetes, skin health, hyperlipidemia, and biomedicine, with a key release fromProfessor Wang Wei’s “Xenotransplantation of Porcine Islet Cells for the Treatment of Type 1 Diabetes,” Professor Zhou Zhiguang’s “Regulatory T Cell Therapy for Type 1 Diabetes,” Professor Chen Chuanpin’s “Research on the Preparation of Microbubble Ultrasound Contrast Agents Using Microfluidic Methods for Next-Generation Drug Delivery Systems,” Professor Zhou Jianda’s “Application Technologies in Repair and Regeneration,” Professor Hu Minyu’s “A Composition for Preventing and Controlling Hyperlipidemia and Its Associated Cardiovascular, Cerebrovascular, or Neuronal Damage,” Professor Zhao Shuang’s “Multispectral Device for Intelligent Detection of Skin Health and Diseases Based on Multimodal Data,” Physician Jiang Xinghua’s “Innovator in Neuromodulation Technologies,” Professor Deng Xu’s “Efficient Synthesis Process for Chiral Homophenylalanine and Pril-class Drugs,” Professor Wang Xiyang’s “Research and Development of a Series of Posterior Spinal Screw-Plate-Rod Systems for Medical Use,” Physician Xiao Yichao’s “Key Instruments and Technologies for Pulsed Electric Field Targeted Ablation,” and Director Ren Caiping’s “Nucleic Acid Aptamer Sequences Targeting Human Nasopharyngeal Carcinoma Cells and Their Applications” — 11 achievements。

Images from the Project Pitch Session

The research leads and team representatives of each project provided detailed introductions to their projects, covering project status, technological innovations and advantages, development plans, collaboration needs, and core teams. To gain a deeper understanding of these innovative projects, numerous investors and corporate representatives, participating both online and offline, engaged in in-depth discussions with the scientists on topics such as technological development, scenario-based applications, core team building, and future development strategies. The atmosphere at the event was highly engaging and vibrant.

Orange Fruit Roadshow is a series of events under “Orange Growth Plan,” a brand dedicated to medical innovation through the translation of scientific research achievements. Initiated by VCBeat, VB100, VCBeat Orange Fruit Bureau, and Danshi Capital, and jointly organized with 13 leading institutions including Sequoia China, Legend Capital, Honghui Capital, Matrix Partners China, Qiming Venture Partners, Mint Angel, Sinovation Ventures, CAS Star, AstraZeneca, BD Medical, Boston Scientific, Ascletis Pharma, and OmicsMD, this event focuses on clinical specialties and adopts an online roadshow format with interactive Q&A sessions. It plans to hold 5–8 online sessions to build a collaboration platform connecting high-quality projects from universities and research institutes with top-tier capital firms and enterprises, thereby accelerating the process of translating scientific achievements into practical applications.